Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Intensity Therapeutics Inc. (INTS : NSDQ)

• Company Description    Intensity Therapeutics Inc. is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. Intensity leverages its DfuseRx(SM) technology platform to create new, proprietary drug formulations, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity Therapeutics Inc. is based in WESTPORT, Conn. Number of Employees: 7

• Price / Volume Information    Yesterday's Closing Price: $0.23 Daily Weekly Monthly 20 Day Moving Average: 3,955,041 shares Shares Outstanding: 49.06 (millions) Market Capitalization: $11.39 (millions) Beta: 3.25 52 Week High: $4.25 52 Week Low: $0.19 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -22.21% -23.58% 12 Week -27.21% -33.88% Year To Date -86.81% -88.21%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1 ENTERPRISE DRIVE SUITE 430 - SHELTON,CT 06484 USA ph: 203-221-7381 fax: - coreirteam@coreir.com http://www.intensitytherapeutics.com

• General Corporate Information    Officers Lewis H. Bender - President; Chief Executive Officer and Chairman Joseph Talamo - Chief Financial Officer John Wesolowski - Principal Accounting Officer and Controller Daniel Donovan - Director Emer Leahy - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45828J103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/12/25 Share - Related Items Shares Outstanding: 49.06 Most Recent Split Date: (:1) Beta: 3.25 Market Capitalization: $11.39 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.06 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.38 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.78 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 63.89% vs. Previous Quarter: 40.91% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -612.44 03/31/25 - -527.85 12/31/24 - -313.39 ROA 06/30/25 - -287.43 03/31/25 - -276.29 12/31/24 - -209.39 Current Ratio 06/30/25 - 1.40 03/31/25 - 0.63 12/31/24 - 1.92 Quick Ratio 06/30/25 - 1.40 03/31/25 - 0.63 12/31/24 - 1.92 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 0.08 03/31/25 - 0.02 12/31/24 - 0.19 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.04 03/31/25 - 0.31 12/31/24 - 0.04 Debt-to-Capital 06/30/25 - 4.17 03/31/25 - 23.39 12/31/24 - 3.63

Powered by Zacks Investment Research ©